INTRODUCTION
Basic Protocol 1 describes a method to generate transgene-free human iPS cells using a retroviral polycistronic reprogramming cassette encoding the Yamanaka reprogramming factors OCT4, SOX2, KLF4, and cMYC linked by picornaviral 2A peptides. LoxP sites flanking the polycistronic cassette enable Cre recombinase-mediated excision. Transfection of Cre mRNA allows for efficient recovery of factor-free human iPS cells as compared with the viral delivery of Cre. The efficient generation of transgene-free human iPS cells, with their closer resemblance to human embryonic stem cells, promises improved performance in vitro and provides invaluable tools for medical research. NOTE: All protocols in this unit require standard tissue culture and sterilization facilities. Cells should be handled under sterile conditions in a Class II Biosafety cabinet.
NOTE:
All human-and mouse-derived cells are incubated in a 37 • C, 5% CO 2 humidified incubator.
NOTE: All equipment and reagents that come into contact with live cells must be sterile, and proper aseptic technique should be used.
BASIC PROTOCOL 1

DIRECT REPROGRAMMING OF HUMAN FIBROBLASTS USING A Cr e-EXCISABLE RETROVIRAL REPROGRAMMING MONOVECTOR
This protocol is used to generate concentrated VSVG-pseudotyped Cre-excisable polycistronic retrovirus and is similar to one previously described (UNIT 4A.1). The virus is then used to infect human fibroblasts to generate iPS cells similarly to the method described (UNITS 4A.1 & 4A.2) .
Materials
293T cells for generating retrovirus (ATCC #CRL11268) growing in a 100-mm tissue culture dish 293T medium (see recipe) Fugene 6 (Roche Applied Science, cat no. 1181509001) DMEM
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Current Protocols in Stem Cell Biology Supplement 21 DMEM/F12 (Invitrogen, cat. no. 10565-018) pE4-OSKM vector (available from author upon request) Gag-Pol (Addgene, clone 8455) VSV-G (Addgene, clone 8454) 10% FBS medium Human fibroblasts Protamine sulfate (Sigma Aldrich, cat no. P4380) PBS Human fibroblast medium (see recipe) Irradiated CF-1 mouse embryonic fibroblast (MEFs) (GlobalStem, cat. no. GSC-6001G) CF1 MEF feeder medium (see 10% FBS medium recipe) 0.05% trypsin (Invitrogen, cat no. 2530054) hESC growth medium (see recipe) Y-27632 (Sigma-Aldrich, cat no. Y0503) Platform rocker 37
• C, 5% CO 2 humidified incubator 6-well plates 10-ml disposable syringe (BD, cat no. 301030) Low protein-binding, 0.45-µm pore size cellulose acetate filter (Pall Life Sciences, cat no. PN4184) 1 × 3-1/2 polyallomer centrifuge tube (Beckman, cat no. 326823) Beckman XL-90 ultracentrifuge 100-mm plates coated with 0.1% gelatin (for gelatin, Sigma-Aldrich, cat no. G1890) Hemacytometer 12-well plates coated with 0.1% gelatin (for gelatin, Sigma-Aldrich, cat no. G1890) Stereomicroscope Cell lifter (Corning, cat no. 3008) Produce VSVG-pseudotyped Cre-excisable retrovirus in 293T cells 1. On the day of transfection for viral production (day 0), aspirate the medium from a 70% to 80% confluent culture of 293T cells growing in a 100-mm tissue culture dish.
2. For each 100-mm dish, add 20 µl of Fugene 6 to 300 µl DMEM and incubate this mixture 15 min at room temperature. Add 2.5 µg pE4-OSKM vector, 2.25 µg Gag-pol, and 0.25 µg VSV-G vector to the mixture and incubate 15 min at room temperature to allow formation of the Fugene/DNA complex.
3. Replace the medium in the 293T cells by aspirating with fresh 10 ml of 293T medium, add 350 µl of Fugene/DNA complex (from step 2) to the dish of 293T cells, and rock it back and forth gently to allow for equal distribution. Incubate dish overnight in a 37 • C, 5% CO 2 incubator.
4. On the morning of day 1, replace the 293T medium containing the Fugene/DNA complexes with fresh 10% FBS medium. Incubate overnight in a 37 • C, 5% CO 2 incubator.
5. On the morning of day 2, plate 1 × 10 6 human fibroblasts per well of a 6-well plate for each desired infection.
6. Forty eight hours after transfection (day 2), under BL2+ conditions, collect viruscontaining supernatant from the 100-mm dish with a 10-ml disposable syringe, and filter the supernatant using a 0.45-µm pore size cellulose acetate filter.
7. Prepare the viral supernatant for ultracentrifugation by transferring the viral supernatant into a 1 × 3-1/2 polyallomer ultracentrifuge tube. Balance the tubes with DMEM.
8. Use the Beckman XL-90 ultracentrifuge to concentrate the retroviral supernatant. Centrifuge the virus 90 min at 177,360 × g, 4 • C.
9. After carefully retrieving the ultracentrifuge tubes containing the virus from the ultracentrifuge, remove the supernatant while avoiding the viral pellet.
10. Add 1 ml DMEM/F12 to the tubes to dissolve the pellet and leave the dissolved pellet undisturbed overnight at 4 • C.
11. Determine the titer of the virus following published protocols (Tiscornia et al., 2006) .
Infect retrovirus into human fibroblasts
12. On day 3, remove the human fibroblasts from the incubator and change medium with fresh human fibroblast medium. Add aliquots of the retroviral supernatants at a multiplicity of infection (MOI) of 5 for the pE4-OSKM virus. Add protamine sulfate at a concentration of 5 µg/ml.
13. One day after infection (day 4), remove the viral supernatant, wash three times with 3 ml PBS for each wash of 5 sec, aspirating PBS between each wash, then add 3 ml of human fibroblast medium. Incubate cells for 3 days in a 37 • C, 5% CO 2 incubator.
Reseed fibroblasts onto CF1 feeders 14. Five days after infection (day 8), seed 1 × 10 4 /cm 2 MEFs in CF1 MEF medium on a 100-mm dish coated with 0.1% gelatin. Incubate overnight in a 37 • C, 5% CO 2 humidified incubator.
15. On day 9, aspirate the medium and wash the infected human fibroblasts (from step 13) once with PBS as in step 13.
16. Add 1 ml of 0.05% trypsin and incubate dish 5 to 10 min in a 37 • C, 5% CO 2 humidified incubator.
17. Add 9 ml of 10% FBS medium to the dish and dissociate the masses of cells by pipetting up and down.
18. After counting cells with a hemacytometer, transfer ∼5 × 10 4 human fibroblast cells into a 100-mm dish containing irradiated CF1 MEFs (prepared in step 14). Incubate overnight in a 37 • C, 5% CO 2 humidified incubator. 19. On the next day and every following day, change medium to 10 ml of hESC medium (KOSR-bFGF). 
Pick colonies
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22. On the next day, prior to picking the nascent colonies, refresh the 12-well plate with 1 ml hESC medium/well. 
37
• C and 65
• C heating blocks Thermal cycler 1.7-ml microcentrifuge tubes, RNase-free Spectrophotometer (NanoDrop) PCR strip Perform 5 phosphorylation of the Cre ORF forward primer 1. Combine the following: 300 pmol primer (3 µl of 100 µl stock) 1 µl (10 U) PNK enzyme 5 µl 10× buffer 50 nmol ATP (0.5 µl of 100 µl stock) 2. Incubate 30 min at 37 • C.
3. Heat-inactivate at 65 • C for 20 min.
4. Add 250 µl TE buffer to make 1 µM stock (100 µl to make 2 µM stock). Purify gel-excised DNA product (Cre recombinase) 8. Combine 5 vol PB buffer to 1 vol reaction (5:1). Mix with pipet and apply to a QIAquick column. Centrifuge 1 min at 7710 × g, 4 • C, and discard the flow-through.
9. Wash column with 750 µl buffer PE. Centrifuge 1 min at 7710 × g, 4 • C, and discard the flow-through.
10. Centrifuge again 1 min at 7710 × g, 4 • C, and place Qiaquick column in a clean 1.7-ml microcentrifuge tube.
11. Elute with water (nuclease-free) or EB buffer. Wait ≥1 min before centrifuging 1 min at 7710 × g, 4 • C.
12. Quantify and quality control PCR product using a NanoDrop machine.
Ligate UTR
13. Ligate the UTRs to the Cre recombinase ORF amplicon isolated above by combining the following for a 20-µl reaction: 19. Perform QIAquick purification as described in steps 8 through 11.
20. Quantify and quality control the purification product by Nanodrop and dilute to 100 ng/µl. 30. Transfer the sample to a filter cartridge (assembled on a collection tube). 37. Quantify the RNA using a Nanodrop machine before proceeding to Antarctic phosphatase treatment.
Perform phosphatase treatment 38. Perform Antarctic phosphatase treatment by adding 10 µl of 10× buffer to each reaction. Then add 3 µl Antarctic phosphatase. Gently mix and incubate the reaction for 30 min at 37 • C.
Inactivate reaction for 5 min at 65
• C.
39. Perform RNA purification with the MEGAclear kit as described above in steps 26 to 35.
40. Quantify the RNA using the Nanodrop.
Each 2× reaction will generally produce ∼50 µg RNA (the expected yield of a 40-µl reaction is generally 40 to 60 µg).
41. Adjust the RNA concentration to 100 ng/µl using RNase-free TE buffer.
42. Aliquot RNA and store at −20 • C or −80 • C. 
EFFICIENT EXCISION OF REPROGRAMMING FACTORS USING mRNA TRANSFECTION OF Cre RECOMBINASE
This protocol describes the use of mRNA transfection of Cre recombinase to excise the reprogramming factor monovector from the primary human iPS cells generated in Basic Protocol 1. 
Materials
Matrigel is frozen at −80 • C, is liquid at 4
• C, and gels rapidly at room temperature.
2. Place a sterile 15-ml conical tube and a cold, sterile bottle of DMEM/F12 into a sterile biosafety cabinet.
3. Remove a Matrigel aliquot (1 mg for two 6-well plates) from the −80 • C freezer and add 1 ml of cold DMEM/F12 to it.
4. Pipet up and down to thaw and dissolve the Matrigel. Transfer to the 15-ml conical tube.
5. Dilute the Matrigel to 0.5 mg/6-well plate (the final volume will be 1 ml/well). For a 1-mg aliquot, add an additional 11 ml of DMEM/F12 to the 15-ml conical.
6. For same-day use, allow 1 hr at room temperature to coat. If plates are to be used >1 hr later, add an additional 1 ml of DMEM/F12 to each well to prevent drying and store at 4 • C until used.
7. If plates are to be stored, add an additional 1 ml of DMEM/F12 to each well, wrap in Parafilm, and store for 7 to 10 days at 2 • to 8 • C.
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Perform single-cell dissociation and low-density plating of pE4 hiPSCs 8. Dissociate a pE4-human iPS cell line at 80% to 90% confluency maintained on CF1 feeders and standard KSR-bFGF conditions with Accutase into single cells in the presence of 10 µM Y-27632 according to manufacturer's instructions.
9. Plate the pE4-hiPSC line at low density (1 to 2 × 10 5 cells per well of a 6-well plate) in mTeSR1 medium containing Y-27632 (10 µM) 24 hr at 37 • C, to enable picking of Cre-excised clones.
Transfect Cre RNA 10. After allowing 1 or 2 days for recovery of pE4-hiPSCs from plating and single-cell dissociation, prepare to transfect with mRNA continuously for 7 days.
11. Dilute 100 ng/µl of Cre mRNA five fold in Opti-MEM basal medium. Dilute 5 µl of RNAiMAX per 1 µg of RNA ten fold in Opti-MEM. Combine these two dilutions and incubate 15 min at room temperature.
12. Take the six-well plate(s) of pE4 hiPSCs out of the 37 • C incubator and aspirate medium. Feed each well with 2 ml of fresh mTeSR1 medium and 50 to 100 ng/ml of B18R interferon inhibitor.
13. After changing the medium, add 120 µl RNA/RNAiMAX complex (from step 11) per well directly to the medium. Return plates to incubator.
14. After 4 to 6 hr, aspirate medium, refresh each well with 2 ml of mTeSR1 medium and 50 to 100 ng/ml of B18R interferon inhibitor.
All media changes should contain B18R when RNA transfection is occurring.
15. Incubate plates overnight in the incubator and repeat this procedure (steps 11 through 14) every day for 7 days.
16. After day 7 of RNA transfection, allow putative Cre-excised hiPSC clones to expand into colonies. After observing colony formation, seed a gelatinized 6-well plate with 1 × 10 4 CF1 MEF feeder cells/cm 2 in ∼2 ml MEF medium (10% FBS/DMEM).
Expand under KSR-bFGF/CF1 conditions 17. After observing colony formation, prepare to transfer Cre-mRNA-transfected pE4-hiPSCs into standard hESC growth conditions (CF1 MEFs and KOSR-bFGF). Remove 6-well plate(s) of CF1 feeders from incubator and replace MEF medium (10% FBS/DMEM) with standard human ES medium (KOSR-bFGF) containing 10 µM Y-27632.
18. Wash the 6-well plate containing the candidate Cre-excised human iPS cells two times with 2 ml of DMEM/F12. Add 2 ml of DMEM/F12 to the dish.
19. Pick Cre-mRNA transfected pE4-hiPSC colonies and transfer into CF1 plate. With 2 ml of DMEM/F12 still in the dish, cut out an iPS colony and separate it from feeder cells under the stereo microscope using a 2-or 10-µl pipet tip and pipettor. Transfer the colony to an individual well of the 6-well plate.
20. Expand candidate Cre-excised human iPS cell clones to at least 50% confluence to identify Cre-excised clones via genomic PCR and for additional characterization.
Screen for transgene-free hiPSC via genomic PCR and Southern blot 21. Collect genomic DNA using the Qiagen DNeasy blood and tissue kit according to the manufacturer's instructions.
22
. Run genomic DNA quantitative real-time PCR using a thermal cycler with primer sets that recognize pE4 retroviral vector. −4 M 2-mercaptoethanol (Invitrogen, cat. no. 21985-023) 50 U penicillin/50 µg/ml streptomycin (Invitrogen, cat. no. 15070063) 5 ng/ml recombinant bFGF (Invitrogen, cat. no. 13256-029) To prepare PBS containing 0.1% bovine serum albumin (BSA), add 50 µl of 10% BSA into 5 ml of PBS. Dissolve 50 µg of bFGF in 5 ml of PBS containing 0.1% BSA (10 µg/ml). Aliquot and store at −20 • C. Add 0.2 ml of 10 µg/ml bFGF into 500 ml of hESC medium before use. Store 2 weeks at 4 • C. 
COMMENTARY Background Information
The ability to generate patient-specific pluripotent stem cells is anticipated to contribute significantly to regenerative medicine (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007; Park et al., 2008a,b) . The protocol described here allows this important cell type to resemble human ES cells even more closely by eliminating the integrated transgenes that may predispose more traditional iPS lines towards residual transgene-mediated differentiation bias or malignant transformation (Soldner et al., 2009) . Although various methods have been devised to generate both murine and human iPS cells without integrated transgenes (Okita et al., 2008; Stadtfeld et al., 2008; Fusaki et al., 2009; Kim et al., 2009; Woltjen et al., 2009; Yu et al., 2009; Zhou et al., 2009; Anokye-Danso et al., 2011) , most protocols to date are limited by extremely low efficiency and technical difficulties. One possible solution to generate research-grade transgene-free human iPS cells is to combine the high efficiency of viral transduction with minimal genetic perturbation. The protocol herein details the generation and characterization of transgene-free human iPS cells using a retroviral construct that expresses four reprogramming factors in tandem on a single "monovector." Flanking loxP sites in the viral LTRs facilitate proviral excision following transient mRNA expression of Cre-recombinase, and the resulting human iPS cells are pluripotent. The chief advantage of the described method is the ease and efficiency of generating transgene-free lines, which promise improved performance in vitro and represent invaluable tools for medical research. Although Cre-mediated excision of the provirus removes all transgenes, a single LoxP remains at each integration site, leaving the possibility that nearby genes could be disturbed. Analysis of the sequences flanking the integration sites and exhaustive characterization could mitigate safety concerns.
Critical Parameters
Several critical parameters have previously been reported to critically influence observation of reprogramming events in human cells (UNITS 4A.1 & 4A.2) . Briefly, first, the quality and titer of the retrovirus is critical; a multiplicity of infection (MOI) of 5 is used for reprogramming with the pE4 monovector. Second, it is desirable to use high-quality, low-passage fibroblasts and to avoid the use of senescent fibroblasts for reprogramming.
When attempting to ligate the UTRs to the ORF, it may be difficult to find ligation conditions that allow for simultaneous annealing of both splints. A gradient temperature approach has been described here and in earlier literature (Warren et al., 2010) in an attempt to avoid this difficulty, but if the double ligation proves too difficult, a sequential ligation can be completed. This approach would first add the 3 UTR, then in a separate reaction add the 5 UTR. A sequential ligation allows for annealing conditions to be designed specifically for a particular splint.
If necessary, the duration of the in vitro reaction may be adjusted somewhat from the 12 hr described in this protocol. The manufacturer's instructions suggest a 2-to 4-hr reaction 
4A.5.15
that can be extended up to 16 hr to increase yield. Increasing the amount of template included in the reaction may also enhance yield. Once the in vitro transcription reaction in completed, it is necessary to maintain strict RNasefree laboratory procedure to prevent degradation of the Cre mRNA. The copy number of the monovector can influence the ease of Cre recombinase-mediated excision. Human iPS cell clones that contain multiple copies of the transgenes may require multiple rounds of Cre mRNA transfection to achieve removal of all integrated reprogramming factors. It is desirable to preselect human iPS clones with a low transgene copy number (single copy is preferable) to reduce the number of rounds of Cre mRNA transfection and the number of LoxP scars left behind. Additionally, when inducing Cremediated proviral excision, chromosome rearrangement and/or translocations may form via recombination among multiple loxP sites (Yu and Bradley, 2001 
Troubleshooting
It is important to distinguish between partially and bona fide reprogrammed colonies. During primary reprogramming of human fibroblasts, early granulated colonies appear; clear-edged colonies that are more hESC-like in morphology appear later and these are more likely to represent human iPS cells. Additionally, the authors' laboratory has found that expression of TRA-1-60, DNMT3B, and REX1 more specifically identifies faithfully reprogrammed colonies (Chan et al., 2009) .
Ensure that the UTR ligation worked by diagnostic PCR using flanking primers and subsequently performing gel electrophoresis to double-check if the product is of the expected size. This is a critical juncture for troubleshooting-if the ligation is unsuccessful (it often requires multiple attempts), attempt either a wider/smaller gradient of temperatures or attempt a sequential ligation. The difficulty lies in that the two splints usually have different annealing conditions, so both will not stick at once.
